158 related articles for article (PubMed ID: 26333016)
21. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features.
Bjornsson J; Short MP; Kwiatkowski DJ; Henske EP
Am J Pathol; 1996 Oct; 149(4):1201-8. PubMed ID: 8863669
[TBL] [Abstract][Full Text] [Related]
22. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
23. Insight into mechanism of oxidative DNA damage in angiomyolipomas from TSC patients.
Habib SL
Mol Cancer; 2009 Mar; 8():13. PubMed ID: 19265534
[TBL] [Abstract][Full Text] [Related]
24. 2,3,5-tris(Glutathion-S-yl)hydroquinone (TGHQ)-mediated apoptosis of human promyelocytic leukemia cells is preceded by mitochondrial cytochrome c release in the absence of a decrease in the mitochondrial membrane potential.
Yang MY; Lau SS; Monks TJ
Toxicol Sci; 2005 Jul; 86(1):92-100. PubMed ID: 15800030
[TBL] [Abstract][Full Text] [Related]
25. Cell-specific regulation of Nrf2 during ROS-Dependent cell death caused by 2,3,5-tris(glutathion-S-yl)hydroquinone (TGHQ).
Zhang F; Munoz FM; Sun L; Zhang S; Lau SS; Monks TJ
Chem Biol Interact; 2019 Apr; 302():1-10. PubMed ID: 30703377
[TBL] [Abstract][Full Text] [Related]
26. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
27. Pathology of hereditary renal cell carcinoma syndromes: Tuberous sclerosis complex (TSC).
Machacek ME; Wu CL; Cornejo KM
Semin Diagn Pathol; 2024 Jan; 41(1):8-19. PubMed ID: 37993384
[TBL] [Abstract][Full Text] [Related]
28. Carcinogen-specific gene expression profiles in short-term treated Eker and wild-type rats indicative of pathways involved in renal tumorigenesis.
Stemmer K; Ellinger-Ziegelbauer H; Ahr HJ; Dietrich DR
Cancer Res; 2007 May; 67(9):4052-68. PubMed ID: 17483316
[TBL] [Abstract][Full Text] [Related]
29. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
30. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
[TBL] [Abstract][Full Text] [Related]
31. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
Ma L; Teruya-Feldstein J; Bonner P; Bernardi R; Franz DN; Witte D; Cordon-Cardo C; Pandolfi PP
Cancer Res; 2007 Aug; 67(15):7106-12. PubMed ID: 17671177
[TBL] [Abstract][Full Text] [Related]
32. Tuberous sclerosis complex: tumors and tumorigenesis.
Borkowska J; Schwartz RA; Kotulska K; Jozwiak S
Int J Dermatol; 2011 Jan; 50(1):13-20. PubMed ID: 21182496
[TBL] [Abstract][Full Text] [Related]
33. Tuberin-deficiency downregulates N-cadherin and upregulates vimentin in kidney tumor of TSC patients.
Liang S; Salas T; Gencaslan E; Li B; Habib SL
Oncotarget; 2014 Aug; 5(16):6936-46. PubMed ID: 25149531
[TBL] [Abstract][Full Text] [Related]
34. New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex.
Lam HC; Nijmeh J; Henske EP
J Pathol; 2017 Jan; 241(2):219-225. PubMed ID: 27753446
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics of renal carcinogenesis.
Walker C
Toxicol Pathol; 1998; 26(1):113-20. PubMed ID: 9502393
[TBL] [Abstract][Full Text] [Related]
36. Molecular genetic basis of renal carcinogenesis in the Eker rat model of tuberous sclerosis (Tsc2).
Hino O; Kobayashi E; Hirayama Y; Kobayashi T; Kubo Y; Tsuchiya H; Kikuchi Y; Mitani H
Mol Carcinog; 1995 Sep; 14(1):23-7. PubMed ID: 7546221
[TBL] [Abstract][Full Text] [Related]
37. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex.
Al-Saleem T; Wessner LL; Scheithauer BW; Patterson K; Roach ES; Dreyer SJ; Fujikawa K; Bjornsson J; Bernstein J; Henske EP
Cancer; 1998 Nov; 83(10):2208-16. PubMed ID: 9827727
[TBL] [Abstract][Full Text] [Related]
38. A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma.
Wilson C; Idziaszczyk S; Parry L; Guy C; Griffiths DF; Lazda E; Bayne RA; Smith AJ; Sampson JR; Cheadle JP
Hum Mol Genet; 2005 Jul; 14(13):1839-50. PubMed ID: 15888477
[TBL] [Abstract][Full Text] [Related]
39. Multifocal renal cell carcinoma in sibs from a chromosome 9 linked (TSC1) tuberous sclerosis family.
Sampson JR; Patel A; Mee AD
J Med Genet; 1995 Nov; 32(11):848-50. PubMed ID: 8592324
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.
Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M
Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
